With India slowly but steadily morphing into a global pharmaceutical R&D hub, scientists have run into short supply.
Global investment major AMP Capital Investors is launching a $500 million equity fund sometime soon this year to invest in infrastructure in India and China. This will be the third such fund from AMP.
The changes would be immediately effective in countries like Columbia, South Korea, Peru and Panama, where FTAs are in the final stages of approval.
The $4 billion tractor-to-IT conglomerate Mahindra & Mahindra is in talks with European fresh produce supply chain and distribution companies to set up a supply joint venture to cater to international and domestic markets.
The picture is becoming bigger for the core sector. Lower margins from infrastructure projects and expectations of a higher yield from real estate projects have seen many a core sector company jumping on the realty bandwagon.
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
The sales of construction companies are expected to rise in the current quarter and financial year on the back of strong order books and increased activity in infrastructure.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
Ranbaxy Laboratories, the country's biggest drugmaker, is all set to focus its energies in developing and marketing niche products where price erosion is minimal
The pace of privatisation of the Indian healthcare segment is expected to be the fastest in the coming years.
Three months after the Foreign Investment Promotion Board put its entry into India on hold, US coffee retail giant Starbucks has sent a revised application to operate single-brand retail stores under a restructured entity.
Rating agencies think repealing the archaic law would help attain greater transparency and efficiency and reduce problems in accessing funds overseas.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
Data from the Central Information Commission, the apex body that hears complaints regarding denial of information under RTI, shows that corporate houses are increasingly using RTI to extract information from public authorities.
Joining the big league of the global hotel chains expanding in India, Hong Kong-based $2 billion JB group will set up as many as 20 hotels and shopping malls in the country over the next three years.
Pfizer's blockbuster drug Viagra (sildenafil citrate), hitherto approved for use in treatment of erectile dysfunction, may soon acquire a new identity as a "life saving drug" in treating pulmonary arterial hypertension in children.
Move raises doubts about the viability of the business model in organised retail.
The venue of the battle by Swiss multinational Novartis AG against the rejection of its patent application for blockbuster cancer drug Gleevac will now shift to the Patent Appellate Board's office.
Australia has joined the UK, USA and Canada in warning its citizens against using unapproved traditional medicines from India and China.
Hetero is the only Indian partner of multinational drug major Roche Scientific for the manufacture and supply of the latter's patented drug, Tamilflu in developing countries.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances